Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Diffuse Intrinsic Pontine Glioma: early-phase trial registry
16 of 29 indexed Diffuse Intrinsic Pontine Glioma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #552 of 28,707 conditions by registered trial count.
29 US clinical trials · 16 currently recruiting · #552 of 28,707 conditions by registered trial count
Diffuse Intrinsic Pontine Glioma: 29 US clinical trials tracked, 16 recruiting.
Diffuse Intrinsic Pontine Glioma is the subject of 29 registered US clinical trials on ClinicalTrials.gov, 16 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 25 in Phase 1-2 (earlier-stage). The most active sponsor is Nationwide Children's Hospital, running 6 of these trials.
Enrollment posture brief
Registry condition diffuse-intrinsic-pontine-glioma
OPEN 16 | RECR 55% | LATE 0 | EARLY 25 | RANK #552 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Dystonia (55% recruiting · 29 trials)
Diffuse Intrinsic Pontine Glioma lists 16 open slots (55% of 29 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Diffuse Intrinsic Pontine Glioma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Diffuse Intrinsic Pontine Glioma is recruiting above its size-band peers.
16 of 29 indexed trials (55.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Diffuse Intrinsic Pontine Glioma research.
Nationwide Children's Hospital accounts for 6 of 29 trials (20.7%). 21 distinct sponsors appear on at least one study for this condition label.
-
Most Diffuse Intrinsic Pontine Glioma trials plan to enrol fewer than 100 people.
Median target enrolment is 37 among the 29 trials that report a genuine target (sentinel values excluded). 20 of those (69%) plan for fewer than 100 participants.
-
Diffuse Intrinsic Pontine Glioma research is mostly interventional.
26 interventional and 3 observational studies make up this index (89.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
29 total, page 1 of 1
International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository
Children's Hospital Medical Center, Cincinnati
NCT03101813
Combination Therapy for the Treatment of Diffuse Midline Gliomas
University of California, San Francisco
NCT05009992
Targeted Pediatric High-Grade Glioma Therapy
Nationwide Children's Hospital
NCT05839379
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Milton S. Hershey Medical Center
NCT06465199
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Nationwide Children's Hospital
NCT05096481
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
NCT05843253
Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma
Children's National Research Institute
NCT01106794
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Seattle Children's Hospital
NCT04185038
Study of Olutasidenib and Temozolomide in HGG
Rigel Pharmaceuticals
NCT06161974
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
Baylor College of Medicine
NCT04099797
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Ann & Robert H Lurie Children's Hospital of Chicago
NCT04943848
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
University of Miami
NCT05956821
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
Emory University
NCT06624371
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Nationwide Children's Hospital
NCT06333899
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
Nationwide Children's Hospital
NCT04655404
FUS Etoposide for DMG
Columbia University
NCT05762419
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Theodore S. Johnson
NCT04049669
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Pfizer
NCT03709680
Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG
Children's Oncology Group
NCT03033992
Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors
Seattle Children's Hospital
NCT05768880
A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma
Nationwide Children's Hospital
NCT03605550
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Children's Oncology Group
NCT04978727
Fimepinostat in Treating Brain Tumors in Children and Young Adults
Sabine Mueller, MD, PhD
NCT03893487
PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy
University of Florida
NCT04837547
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Julie Krystal
NCT01837862
A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
Children's Hospital Medical Center, Cincinnati
NCT03355794
Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
M.D. Anderson Cancer Center
NCT02420613
CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas
Luca Szalontay
NCT04264143
Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma
University of Colorado, Denver
NCT02992015
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 19 |
| Phase 2 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Diffuse Intrinsic Pontine Glioma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Diffuse Intrinsic Pontine Glioma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Diffuse Intrinsic Pontine Glioma page
29 registered trials, 16 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 16 Diffuse Intrinsic Pontine Glioma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Nationwide Children's Hospital sponsors the most Diffuse Intrinsic Pontine Glioma trials on record, review their full trial history before evaluating a specific study. See Nationwide Children's Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diffuse Intrinsic Pontine Glioma condition card totals 29 registered trials; most-linked intervention Temozolomide; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.